Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine – FLU-02-IB

Overview

Prospective cohort study to evaluate the safety and immunogenicity of the Butantan Influenza vaccine (Fragmented and Inactivated) among healthy adults with 18 to 59 years of age and elderly older than 60 years of age.

Full Title of Study: “Prospective Cohort Study to Evaluate Safety and Immunogenicity of Butantan Seasonal”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 2014

Detailed Description

Prospective cohort study to assess safety of one dose of theButantan Influenza vaccine (Fragmented and Inactivated) in the first 3 days after vaccination and its immunogenicity 21 days after vaccination among healthy adults with 18 to 59 years of age and elderly older than 60 years of age..

Interventions

  • Biological: Butantan Influenza Trivalent, Fragmented and Inactivated vaccine

Arms, Groups and Cohorts

  • Healthy adults group
    • Healthy men and women between 18 and 59 years of age.
  • Elderly group
    • Elderly over 60 years old.

Clinical Trial Outcome Measures

Primary Measures

  • Adverse events in the first 3 days post vaccination (Safety)
    • Time Frame: Three days
    • Solicited and unsolicited local and systemic adverse reactions reported by the participants until Day 3 after vaccination.
  • Antibody response to each of the vaccine strains 21 days post vaccination (Immunogenicity)
    • Time Frame: 21 days
    • Antibody response to each of the vaccine´s strains as measured by: % seroconversion and/or increase in the geometric mean of hemagglutination inhibition (HAI) titers and/or % seroprotection.

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy adults, male or female aged 18 to 59 – Elderly aged 60 years completed and above – To be available to participate in the study throughout its duration (approximately 21 days) – To have medical indication to be vaccinated against influenza – To demonstrate intention to participate in the study, as documented by signature in the study´s informed consent form. Exclusion Criteria:

  • Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as clinical history and/or physical examination (except hypertension under control among the elderly) – Compromised immune system diseases including: HIV, diabetes mellitus, cancer (except basal cell carcinoma) and autoimmune diseases – Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements – Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history – Known systemic hypersensitivity to eggs or to any component of the vaccine – History of severe adverse reaction after previous administration of an Influenza vaccine within 6 weeks following vaccination

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Butantan Institute
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.